2024
Proceedings from an international consensus meeting on ablation in urogenital diseases
Iezzi R, Contegiacomo A, De Filippis A, Gunn A, Atwell T, Mcclure T, Jing Z, Posa A, Scrofani A, Maresca A, Madoff D, Goldberg S, Kelekis A, Filippiadis D, Sala E, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Into Imaging 2024, 15: 267. PMID: 39514046, PMCID: PMC11549275, DOI: 10.1186/s13244-024-01841-2.Peer-Reviewed Original ResearchInternational Consensus MeetingAblation techniqueIntermediate-risk prostate cancerImage-guided ablation techniquesPreoperative surgical riskManagement of oncological diseasesRenal cell carcinomaConsensus meetingTraditional surgical treatmentGenitourinary tract diseaseFibroid SymptomCell carcinomaProstate cancerSurgical riskAblation therapyImprove patient outcomesTumor managementSurgical treatmentMechanism of actionEffective alternativeTherapeutic alternativeSite of applicationEffective treatmentUrogenital diseasesOncological diseases
2023
Modalities to Deliver Cell Therapy for Treatment of Chronic Limb Threatening Ischemia
Setia O, Lee S, Dardik A. Modalities to Deliver Cell Therapy for Treatment of Chronic Limb Threatening Ischemia. Advances In Wound Care 2023, 13: 253-279. PMID: 37002893, PMCID: PMC11305013, DOI: 10.1089/wound.2022.0114.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic limb threatening ischemiaPeripheral arterial diseaseSevere peripheral arterial diseaseLimb threatening ischemiaClinical trialsCell therapyStem cell therapyIschemic limbsFeasible therapeutic alternativePromising treatment optionPre-clinical studiesCell deliveryPAD patientsArterial diseaseClinical benefitTreatment optionsSurgical methodsTherapeutic alternativeBest modalityHigh riskLimb lossSevere formTherapeutic benefitPatientsTherapy
2022
O-163 Pathophysiology – what’s new
Taylor H. O-163 Pathophysiology – what’s new. Human Reproduction 2022, 37: deac105.073. DOI: 10.1093/humrep/deac105.073.Peer-Reviewed Original ResearchSystemic diseaseGynecological diseasesOral gonadotropin-releasing hormone antagonistClinical diagnosisLow-dose oral contraceptivesGonadotropin-releasing hormone antagonistEndometrial-like tissueFirst-line medicationAccurate clinical diagnosisFemale reproductive tractOral contraceptivesPrompt treatmentSystemic inflammationGnRH antagonistPain sensitizationProgesterone resistanceSymptomatic womenClinical presentationRetrograde menstruationEndometriosis careHormone antagonistReproductive ageEffective therapyTherapeutic alternativeMood disorders
2021
COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences
Sanchez-Russo L, Billah M, Chancay J, Hindi J, Cravedi P. COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences. Journal Of Clinical Medicine 2021, 10: 900. PMID: 33668833, PMCID: PMC7956338, DOI: 10.3390/jcm10050900.Peer-Reviewed Original ResearchAcute kidney injuryKidney replacement therapyKidney injuryReplacement therapyClinical presentationCOVID-19-Related Acute Kidney InjuryMajor tertiary care centerAggressive clinical presentationTertiary care centerAcute peritoneal dialysisCOVID-19 patientsCoronavirus disease 2019Definitive pathogenesisIll patientsHistopathologic evidencePeritoneal dialysisTherapeutic challengeMultiple etiologiesCare centerTherapeutic alternativeChronic consequencesCommon findingHealthcare workersDisease 2019High incidenceEndometriosis is a chronic systemic disease: clinical challenges and novel innovations
Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. The Lancet 2021, 397: 839-852. PMID: 33640070, DOI: 10.1016/s0140-6736(21)00389-5.Peer-Reviewed Original ResearchConceptsSystemic diseaseGynaecological diseaseOral gonadotropin-releasing hormone antagonistClinical diagnosisLow-dose oral contraceptivesGonadotropin-releasing hormone antagonistEndometrial-like tissueChronic systemic diseaseFirst-line medicationAccurate clinical diagnosisFemale reproductive tractPain sensitisationOral contraceptivesPrompt treatmentSystemic inflammationGnRH antagonistProgesterone resistanceSymptomatic womenClinical presentationRetrograde menstruationEndometriosis careHormone antagonistReproductive ageEffective therapyTherapeutic alternative
2017
Progranulin derivative Atsttrin protects against early osteoarthritis in mouse and rat models
Wei J, Fu W, Ding Y, Hettinghouse A, Lendhey M, Schwarzkopf R, Kennedy O, Liu C. Progranulin derivative Atsttrin protects against early osteoarthritis in mouse and rat models. Arthritis Research & Therapy 2017, 19: 280. PMID: 29258611, PMCID: PMC5735869, DOI: 10.1186/s13075-017-1485-8.Peer-Reviewed Original ResearchConceptsTherapeutic effectOA modelPain-related markersAnti-catabolic effectsRole of progranulinDegenerative joint diseaseMurine OA modelMultiple murine modelsNew therapeutic alternativesTumor necrosis factor receptorIntra-articular deliveryNecrosis factor receptorInflammatory arthritisPGRN deficiencyOA phenotypeSafranin O stainingTherapeutic alternativeRat modelJoint diseaseOsteoarthritis progressionPreventative effectMurine modelCartilage degradationDegenerative factorsEarly osteoarthritis
2016
Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.
Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. DOI: 10.1200/jco.2016.34.2_suppl.252.Peer-Reviewed Original ResearchResidual tumor fociMesenchymal growth factorsRadical prostatectomy specimensClonal heterogeneityTumor initiating cellsProstate cancer organoidsMechanisms of resistanceMetastatic PCPC progressionTherapeutic alternativeTumor fociNormal epitheliumPatient stem cellsProstatectomy specimensMolecular alterationsPotential efficacyCancer organoidsSelf-renewal capacityInitiating cellsGrowth factorBiologic responseEarly passagesGrowth inhibitionStem cellsEpigenetic alterations
2008
Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression
Vieyra-Reyes P, Mineur YS, Picciotto MR, Túnez I, Vidaltamayo R, Drucker-Colín R. Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. Brain Research Bulletin 2008, 77: 13-18. PMID: 18582540, PMCID: PMC2771408, DOI: 10.1016/j.brainresbull.2008.05.007.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntidepressive AgentsBehavior, AnimalDepressionDisease Models, AnimalDrug Administration ScheduleExploratory BehaviorInjections, IntraperitonealMaleMotor ActivityNicotineOlfactory BulbPsychology, ComparativeRatsRats, Long-EvansRats, WistarSelf AdministrationSpecies SpecificitySwimmingTranscranial Magnetic StimulationConceptsDepression-like symptomsTranscranial magnetic stimulationAntidepressant-like effectsWistar ratsMagnetic stimulationOlfactory bulbectomyRat strainsDaily transcranial magnetic stimulationOlfactory bulbectomy rat modelEffects of nicotineOral nicotine intakeOral intakeDepression managementSwim testTherapeutic alternativeNicotine intakeRat modelLong-Evans rat strainDepression susceptibilitySymptomsLong-EvansNicotineInnate differencesRatsBulbectomy
2007
Resistência e refratariedade no transtorno obsessivo-compulsivo
Ferrão Y, Diniz J, Lopes A, Shavitt R, Greenberg B, Miguel E. Resistência e refratariedade no transtorno obsessivo-compulsivo. Brazilian Journal Of Psychiatry 2007, 29: s66-s76. PMID: 18172943, DOI: 10.1590/s1516-44462006005000059.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsBehavior TherapyClinical Trials as TopicCombined Modality TherapyDrug ResistanceDrug ToleranceFamily RelationsHumansMeta-Analysis as TopicObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotherapySelective Serotonin Reuptake InhibitorsConceptsObsessive-compulsive disorder patientsObsessive-compulsive disorderTherapeutic alternativeDisorder patientsConventional treatmentEffective therapeutic alternativeCompulsive disorder patientsAvailable treatmentsTreatment responseClinical challengeTreatment resistanceSymptom remissionAdequate treatmentPatient sufferingPatientsCurrent conceptsRemissionMore studiesTreatmentDisordersSignificant numberLiterature reviewUnanswered questionsExtrinsic factors
2002
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002, 3: 10-15. PMID: 15016169, DOI: 10.1034/j.1399-5448.2002.30103.x.Peer-Reviewed Original ResearchDiabetes programContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyDiabetes-related adverse eventsDaily insulin dosesMean HbA1c levelPrimary efficacy outcomeSevere hypoglycemic eventsPatients 18 monthsPrimary safety measureInsulin infusion therapyYr of ageEfficacy outcomesHbA1c levelsAdverse eventsInjection therapyYounger patientsPump treatmentDiabetes controlHypoglycemic eventsInsulin dosesInfusion therapyTherapeutic alternativeClinic settingClinical data
2000
Evaluation of Therapeutic Strategies: A New Method for Balancing Risk and Benefit
Troche C, Paltiel A, Makuch R. Evaluation of Therapeutic Strategies: A New Method for Balancing Risk and Benefit. Value In Health 2000, 3: 12-22. PMID: 16464177, DOI: 10.1046/j.1524-4733.2000.31002.x.Peer-Reviewed Original ResearchPatient preferencesDose-related efficacyPatients' subjective assessmentPatient-specific preferencesSpecific therapeutic interventionsClinical trial informationEfficacy-toxicity tradeDose prescribedSafety profileTherapeutic alternativeAcceptable efficacyDose intervalSubjective assessmentTherapeutic strategiesTherapeutic interventionsDrug efficacyDifferent patientsTrial informationDifferent drugsDose rangeEfficacyDifferent efficacyDrugsPatientsBalancing Risks
1997
Concurrence of Graves' Disease and Dysplastic Cerebral Blood Vessels of the Moyamoya Variety
Tendler BE, Shoukri K, Malchoff C, MacGillivray D, Duckrow R, Talmadge T, Ramsby GR. Concurrence of Graves' Disease and Dysplastic Cerebral Blood Vessels of the Moyamoya Variety. Thyroid 1997, 7: 625-629. PMID: 9292953, DOI: 10.1089/thy.1997.7.625.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyDisease 10 yearsGraves' diseaseIodine therapyAcute cerebrovascular ischemiaSafe therapeutic alternativeLong-term efficacyCerebral blood vesselsAutoimmune mechanismsCerebrovascular ischemiaMoyamoya phenomenonMoyamoya diseaseAntithyroid drugsOptimal treatmentCerebral vesselsCaucasian womenTherapeutic alternativeHyperthyroidismDiseasePatientsBlood vesselsLimited experienceTherapyVesselsThyroidectomy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply